5International Diabetes Federation. Diabetes Arias, Second edition. 2003.
6International Diabetes Federation. Diabetes Arias, Third edition. 2007.
7中华人民共和国卫生部.2007中国卫生统计纪要.
8Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005,353:2643-2653.
9Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes ( UKPDS 35 ) : prospective observational study. BMJ, 2000,321:405- 412.
10Gaede P, Vedel P, Larsen N, et al. Muhifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003,348:383-393.
6Byrne CD, Olufadi R, Bruce KD, et al. Metabolic disturbances in non-alcoholic fatty liver disease [ J ]. Clin Sci (Lond), 2009,116 (7) :539-564.
7Angulo P. Nonalcoholic fatty liver disease [ J ]. N Engl J Med, 2002,346(16) :1221-1231.
8Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statementon NAFLD/NASH based on the EASL 2009 special conference [ Jl. J Hepato1,2010,53 (2) :372 - 384.
9Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epi-phe- nomenon[ J]. Diabetologia ,2008,51 ( 11 ) : 1947 - 1953.
10Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the meta- bolic syndrome [ J 1. Am J Med Sci,2005,330 (6) : 326 - 335.
